Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday

Denali Therapeutics (NASDAQ:DNLI) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $19.23 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $23.77. The firm has a market cap of $2.82 billion, a PE ratio of -6.61 and a beta of 1.02. The firm’s fifty day moving average is $18.54 and its 200-day moving average is $16.76.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wedbush lowered their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. JPMorgan Chase & Co. raised their target price on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. BTIG Research reissued a “buy” rating and issued a $32.00 price target on shares of Denali Therapeutics in a research note on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Finally, Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a research note on Monday, November 17th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Denali Therapeutics has a consensus rating of “Buy” and an average target price of $32.27.

Insider Activity

In other news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the transaction, the insider owned 282,828 shares of the company’s stock, valued at $4,666,662. This represents a 5.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock worth $1,210,000 after acquiring an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the last quarter. Empowered Funds LLC lifted its stake in Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after purchasing an additional 2,052 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Denali Therapeutics by 13.5% in the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after purchasing an additional 13,517 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 1.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock valued at $2,681,000 after purchasing an additional 3,210 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.